8-K
filed July 15, 2026, 9:03 AM ET
ticker NUVL
CIK 0001861560
M&A
confidence high
sentiment neutral
materiality 1.00
GSK completes $10.6B acquisition of Nuvalent; tender offer accepted, merger effective July 15, 2026
Nuvalent, Inc.
- Tender offer closed with 91.3% of shares tendered; all validly tendered shares accepted at $124.00 per share.
- Merger completed under DGCL Section 251(h); Nuvalent becomes wholly owned subsidiary of GSK.
- Total equity value approximately $10.6 billion; funded from GSK credit facilities.
- All prior directors and officers resigned; replaced by GSK appointees (Justin Huang, Kevin Ryan, Hatixhe Hoxha).
- Shares to be delisted from Nasdaq; company intends to file Form 15 to suspend SEC reporting.
Featured in Daily 8-K Digest
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Justin T. Huang was appointed as Director at Nuvalent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christy Oliger resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin T. Ryan was appointed as Vice President and Treasurer at Nuvalent, Inc..
- Action
- appointed
- Role
- Vice President and Treasurer
Exact text from the filing
Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anna Protopapas resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Grant C. Bogle resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
James R. Porter, Ph.D. resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sapna Srivastava, Ph.D. resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Hatixhe Hoxha was appointed as Assistant Secretary at Nuvalent, Inc..
- Action
- appointed
- Role
- Assistant Secretary
Exact text from the filing
Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ron Squarer resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Cameron A. Wheeler, Ph.D. resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael L. Meyers, M.D., Ph.D. resigned as Director at Nuvalent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Justin T. Huang was appointed as President and Secretary at Nuvalent, Inc..
- Action
- appointed
- Role
- President and Secretary
Exact text from the filing
Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin T. Ryan was appointed as Director at Nuvalent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.